Zilovertamab vedotin (ZV), an antibody drug conjugate which is capable to target the extracellular domain of ROR1, conjugated with the anti-microtubule cytotoxin monomethyl auristatin E was evaluated on 32 patients with MCL, CLL, DLBCL, follicular lymphoma, marginal zone lymphoma or Richter transformation lymphoma and showed no unexpected toxicities and antitumor activity [108]. The gene discussed is ROR1; the disease is diffuse large B-cell lymphoma.